Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

48.37 +0.20 (+0.42%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

40 41 Next >

Is Sanofi Gaining or Losing Market Support? ↗

September 24, 2025

Via Benzinga

FDA Delays Key Sanofi Multiple Sclerosis Drug Decision ↗

September 22, 2025

Sanofi's tolebrutinib review for non-relapsing multiple sclerosis has been extended by the FDA until December 2025.

Via Benzinga

Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion

September 22, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Sanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good Tolerability ↗

September 17, 2025

Sanofi reports show significant improvements in hidradenitis suppurativa symptoms, with higher response rates and reduced lesions.

Via Benzinga

Sanofi’s New Experimental Eczema Drug Meets Goals Of Late-stage Trial, But Wall Street Expected More ↗

September 04, 2025

Via Stocktwits

Novavax CFO Says Sanofi To Cover Majority Of Future Nuvaxovid Study Costs, Retail Urges Partnership Diversification ↗

August 06, 2025

Via Stocktwits

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit ↗

September 15, 2025

AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and foreign capital inflows.

Via Benzinga

Topics Government

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again ↗

September 08, 2025

The company is working on a treatment for an autoimmune disease that affects the muscles.

Via Investor's Business Daily

Roblox To Rally Around 34%? Here Are 10 Top Analyst Forecasts For Monday ↗

September 08, 2025

Via Benzinga

This Veeva Systems Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

September 08, 2025

Via Benzinga

Why Nektar Therapeutics Rippled Higher This Week ↗

September 05, 2025

The company's competitive positioning might be stronger now, after disappointing results from a key rival.

Via The Motley Fool

Topics Intellectual Property

What's Going On With Nektar Therapeutics Stock On Thursday? ↗

September 04, 2025

Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results.

Via Benzinga

Why Is Sanofi Stock Falling Thursday? ↗

September 04, 2025

William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects shaping their market potential.

Via Benzinga

Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors ↗

September 04, 2025

Sanofi's potential successor to Dupixent, amlitelimab, failed to meet investor expectations in a late-stage trial, raising doubts about its dermatology franchise.

Via Benzinga

Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar' ↗

September 04, 2025

Can anything beat out Dupixent's "compelling bar" for effectiveness?

Via Investor's Business Daily

C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

September 04, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 04, 2025

Via Benzinga

Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts ↗

August 11, 2025

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to...

Via Benzinga

Topics Lawsuit

This Monster Beverage Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗

August 08, 2025

Via Benzinga

RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program ↗

August 06, 2025

Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue.

Via Benzinga

Topics Lawsuit

Novavax Ups Outlook, Eyes Stronger Nuvaxovid Sales ↗

August 06, 2025

Novavax beats Q2 expectations with $239 million in revenue, lifts 2025 guidance, and reports profit as costs decline and commercial rights shift to Sanofi.

Via Benzinga

Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZeneca ↗

August 05, 2025

Via Stocktwits

What's Driving the Market Sentiment Around Sanofi? ↗

August 04, 2025

Via Benzinga

2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts ↗

August 03, 2025

These biotech businesses look compelling for very different reasons.

Via The Motley Fool

Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients ↗

August 01, 2025

FDA approves Novo Nordisk's Alhemo for hemophilia A and B without inhibitors, following strong Phase 3 results showing reduced bleeding episodes.

Via Benzinga

Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines ↗

August 01, 2025

Regeneron Q2 revenue rose 4% to $3.68 billion, driven by Dupixent and antibody profits, while FDA delays impacted Eylea HD and odronextamab approvals.

Via Benzinga

Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗

July 31, 2025

Via Stocktwits

Topics Government

Options Corner: Sanofi's Post-Earnings Drama Delivers A Contrarian Discount ↗

July 31, 2025

Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential contrarian discount.

Via Benzinga

Topics Earnings

Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales ↗

July 31, 2025

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

40 41 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.